Skip to main content
SpringerLink
Log in

RANK ligand et métastases osseuses

  • Chapter
Les thérapies ciblées

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 387 Accesses

Abstrait

Les cellules tumorales secrètent des facteurs ostéolytiques dont la plupart agissent via la production par les ostéoblastes de RANKL, facteur de la différenciation des ostéoclastes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Nakagawa N, Kinosaki M, Yamaguchi K, et al. (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253: 395–400

    Article  PubMed  CAS  Google Scholar 

  2. Hsu H, Lacey DL, Dunstan CR, et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540–5

    Article  PubMed  CAS  Google Scholar 

  3. Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nav Rev Genet 4: 638–49

    Article  CAS  Google Scholar 

  4. Simonet WS, Lacey DL, Dunstan CR, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–19

    Article  PubMed  CAS  Google Scholar 

  5. Burgess TL, Qian Y, Kaufman S, et al. (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Bioll 45: 527–38

    Article  Google Scholar 

  6. Corey E, Brown LG, Kiefer JA, et al. (2005) Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65: 1710–8

    Article  PubMed  CAS  Google Scholar 

  7. Grimaud E, Soubigou L, Couillaud S, et al. (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163: 2021–31

    PubMed  CAS  Google Scholar 

  8. Lacey DL, Timms E, Tan HL, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–76

    Article  PubMed  CAS  Google Scholar 

  9. Dougall WC, Glaccum M, Charrier K, et al. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412–24

    Article  PubMed  CAS  Google Scholar 

  10. Mizuno A, Amizuka N, Irie K, et al. (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247: 610–5

    Article  PubMed  CAS  Google Scholar 

  11. Morony S, Capparelli C, Sarosi I, et al. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61: 4432–6

    PubMed  CAS  Google Scholar 

  12. Vanderkerken K, De Leenheer E, Shipman C, et al. (2003) Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63: 287–9

    PubMed  CAS  Google Scholar 

  13. Honore P, Luger NM, Sabino MA, et al. (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6: 521–8

    Article  PubMed  CAS  Google Scholar 

  14. Sordillo EM, Pearse RN (2003) RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 97: 802–12

    Article  PubMed  Google Scholar 

  15. Zhang J, Dai J, Qi Y, et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235–44

    Article  PubMed  CAS  Google Scholar 

  16. Body JJ, Greipp P, Coleman RE, et al. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97: 887–92

    Article  PubMed  Google Scholar 

  17. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655–64

    Article  PubMed  CAS  Google Scholar 

  18. Yonou H, Ochiai A, Goya M, et al. (2004) Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 58: 406–13

    Article  PubMed  Google Scholar 

  19. Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10–20

    PubMed  Google Scholar 

  20. Padalecki SS, Carreon MR, Grubbs B, et al. (2005) Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11: 162–5

    Google Scholar 

  21. Mundy GR (2002) Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer 2: 584–93

    Article  PubMed  CAS  Google Scholar 

  22. Bhatia P, Sanders MM, Hansen MF (2005) Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11: 162–5

    PubMed  CAS  Google Scholar 

  23. Chen G, Sircar K, Aprikian A, et al. (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 289–98

    Google Scholar 

  24. Farrugia AN, Atkins GJ, To LB, et al. (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438–45

    PubMed  CAS  Google Scholar 

  25. Huang L, Xu J, Wood DJ, Zheng MH (2000) Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156: 761–7

    PubMed  CAS  Google Scholar 

  26. Huang L, Cheng YY, Chow LT, et al. (2003) Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol 56: 116–20

    Article  PubMed  CAS  Google Scholar 

  27. Granchi D, Amato I, Battistelli L, et al. (2004) In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 111: 829–38

    Article  PubMed  CAS  Google Scholar 

  28. Tada T, Jimi E, Okamoto M, et al. (2005) Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 116: 253–62

    Article  PubMed  CAS  Google Scholar 

  29. Fiumara P, Snell V, Li Y, et al. (2001) Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 98: 2784–90

    Article  PubMed  CAS  Google Scholar 

  30. Brown JE, Cook RJ, Major P, et al. (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59–69

    PubMed  CAS  Google Scholar 

  31. Coleman RE, Major P, Lipton A, et al. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the biphosphonate zoledronic acid. J Clin Oncol 23: 4925–35

    Article  PubMed  CAS  Google Scholar 

  32. Oefelein MG, Ricchiuti V, Conrad W, et al. (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168: 1005–7

    Article  PubMed  Google Scholar 

  33. Roux S, Meignin V, Quillard J, et al. (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117: 86–92

    Article  PubMed  CAS  Google Scholar 

  34. Terpos E, Szydlo R, Apperley JF, et al. (2003) Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064–9

    Article  PubMed  CAS  Google Scholar 

  35. Bekker PJ, Holloway DL, Rasmussen AS, et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059–66

    Article  PubMed  CAS  Google Scholar 

  36. McClung MR, Lewiecki EM, Cohen SB, et al. (2006) AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–31

    Article  PubMed  CAS  Google Scholar 

  37. Rifkin WD (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006354: 2390–1

    Google Scholar 

  38. Hortobagyi GN, Theriault RL, Porter L, et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785–91

    Article  PubMed  CAS  Google Scholar 

  39. Body JJ, Diel IJ, Lichinitser MR, et al. (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399–405

    Article  PubMed  Google Scholar 

  40. Saad F, Gleason DM, Murray R, et al. (2004) Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879–82

    Article  PubMed  CAS  Google Scholar 

  41. Berenson JR, Lichtenstein A, Porter L, et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488–93

    Article  PubMed  CAS  Google Scholar 

  42. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527–34

    Article  PubMed  Google Scholar 

  43. Markowitz GS, Fine PL, Stack JI, et al. (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281–9

    Article  PubMed  CAS  Google Scholar 

  44. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676–9; discussion 1676-9

    Article  PubMed  CAS  Google Scholar 

  45. Hillner BE, Ingle JN, Chlebowski RT, et al. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042–57

    Article  PubMed  CAS  Google Scholar 

  46. Body JJ, Facon T, Coleman RE, et al. (2006) A study of biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221–28

    Article  PubMed  CAS  Google Scholar 

  47. Peterson MC, Jang G, Kim W, et al. (2006) Selection of a phase III dose regimen for denosumab based on pharmacokinetic, pharmacodynamic, and safety data from multiple subcutaneous dosing regimens in breast cancer patients with bone metastases. Proc ASCO, Abstr 3086

    Google Scholar 

  48. Lipton A, Alvarado C, De Boer R, et al. (2006) Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous biphosphonates. Proc ASCO, Abstr 512

    Google Scholar 

  49. Roudier M, Morrissey C, Huang L, et al. (2007) Immunohistochemical detection in post-mortem specimens of RANK/RANKL/OPG in prostate cancer bone and soft tissue metastases. Proceedings of The prostate cancer symposium, Abstr 62

    Google Scholar 

  50. Fizazi K, Bosserman L, Lipton A, et al. (2007) Phase II randomized trial of denosumab in patients with bone metastases from prostate cancer and elevated urineN-telopeptide levels after receiving zoledronic acid. Proceedings of The prostate cancer symposium, Abstr 272

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département ďoncologie médicale, Institut Curie, 26, rue ďUlm, 75005, Paris

    Philippe Beuzeboc

Authors
  1. Philippe Beuzeboc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France

About this chapter

Cite this chapter

Beuzeboc, P. (2008). RANK ligand et métastases osseuses. In: Les thérapies ciblées. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36008-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36008-4_9

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36007-7

  • Online ISBN: 978-2-287-36008-4

Publish with us

Policies and ethics

Search

Navigation